FTM: Agreed, Sonoma,its people and weather and wine are great. I'm there weekly on Mon.PMs. Thanks for the reminder re. Duramycin binding to a chemically close sibling "PE" (instead of PS). I always timed your sebatical from here with appearance of Thorpe's paper and patents re. Duramycin. Anyway, here is a good potential app for PPHM anti-PS/anti-PE patent portfolio. It also reinforces my belief there is a huge Chinese interest in PPHM that is not noted here. The article is in Apoptosis. 2014 Jan 24. [Epub ahead of print] Positron emission tomography imaging of cell death with [18F]FPDuramycin. Yao S, Hu K, Tang G, Liang X, Du K, Nie D, Jiang S, Zang L.
The noninvasive imaging of cell death, including apoptosis and necrosis, is an important tool for the assessment of degenerative diseases and in the monitoring of tumor treatments. Duramycin is a peptide of 19-amino acids. It binds specifically to phosphatidylethanolamine a novel molecular target for cell death. N-(2-18F-Fluoropropionyl)duramycin ([18F]FPDuramycin) was prepared as a novel positron emission tomography (PET) tracer from the reaction of duramycin with 4-nitrophenyl 2-[18F]fluoropropionate ([18F]NFP). Compared with control cells (viable tumor cells), the in vitro binding of [18F]FPDuramycin with apoptotic cells induced by anti-Fas antibody resulted in a doubling increase, while the binding of [18F]FPDuramycin with necrotic cells induced by three freeze and thaw cycles resulted in a threefold increase. Biodistribution study in mice exhibited its rapid blood and renal clearance and predominant accumulation in liver and spleen over 120 min postinjection. Small-animal PET/CT imaging with [18F]FPDuramycin proved to be a successful way to visualize in vivo therapeutic-induced tumor cell death. In summary, [18F]FPDuramycin seems to be a potential PET probe candidate for noninvasive visualization of in vivo cell death sites induced by chemotherapy in tumors.
